Fenestrin-2
Second RGD-motif platelet aggregation inhibitor paralog from Asiaticobdella fenestrata — Schulz 2025 sialotranscriptome.
Preclinical / mechanisticLast updated: 2026-05-27 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Second RGD-motif platelet aggregation inhibitor paralog from Asiaticobdella fenestrata — Schulz 2025 sialotranscriptome.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
Fenestrin-2's in vitro platelet aggregation inhibition does NOT establish clinical efficacy. No FDA-approved derivative exists; activity in non-Hirudo species does not extend to K040187 medicinal leech therapy.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Preclinical
- Molecular weight
- 5,000 Da
- Source species
- Asiaticobdella fenestrata
- Discovered
- 2025 · Schulz L et al.
Biological Targets
- → platelet integrin αIIbβ3 (via N-terminal RGD motif)
Key Citations
- Schulz L et al. (2025), Parasitol Res · PMID 41198932
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Decorsin
RGD-containing peptide inhibiting platelet GP IIb/IIIa receptor — eptifibatide ancestor.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.